In the study, the protective effect of plasma protein from Tachypleus tridentatus (PPTT) on acute kidney injury (AKI) and the related molecular mechanisms were first investigated by Western blotting analyses, TdT-mediated dUTP Nick-End Labeling (TUNEL) assay, and immunohistochemistry. It was found that PPTT had an obviously inhibitory effect on Reactive oxygen species (ROS) in cyclophosphamide (CTX)-exposed mice. Furthermore, results demonstrated that the renal cell death mode is due to inducing apoptosis and autophagy inhibited by dose-dependent PPTT in mice treated with CTX by decreasing the protein expression of bax, beclin-1, and LC3 and increasing the expression of bcl-2. Moreover, the p38 MAPK and PI3K/Akt signaling pathways were observed to take part in the PPTT-induced renal cell growth effect by enhancing the upregulation of the expression of Akt and p-Akt as well as the downregulation of the expression of p38 and p-p38, which indicated a PPTT ameliorating effect on AKI CTX-induced in mice through p38 MAPK and PI3K/Akt signaling pathways. Briefly, this article preliminarily studies the mechanism of the PPTT ameliorating effect on AKI CTX-induced in mice, which helps to provide a reference for PPTT clinical application in AKI therapy.
Based on the bioactivities of blood protein, the nutritional appraisal and antidiabetic activity of a kind of mixed plasma proteolytic peptide from Tachpleus tridentatus (PPPT) were studied in this work. Results indicated that the amino acid level of PPPT could meet an adult’s FAO/WHO recommended standard; PPPT also manifested inhibitory activity on α-glucosidase with IC50 at 2.62 mg/mL in vitro, and relieved symptoms of type II diabetic mouse in vivo by improving glucose tolerance, increasing insulin secretion by 5.15 mIU/L in the PPPT-4 group and by 4.54 mIU/L in the PPPT-1 group, reducing blood glucose values to nearly normal levels 120 min after intragastric administration, and restoring pathological damage in the thymus. Thus, PPPT can be developed into both a healthcare product and an adjuvant for type II diabetes in the future.